Darifenacin

DB00496ApprovedInvestigationalSmall moleculeAnticholinergic AgentsMuscarinic Antagonists

Darifenacin is an M3 muscarinic receptor blocker used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions.

Chemical structure of Darifenacin
Mechanism
Curator reviewed
Primary indication
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.Curator reviewed · 1 structured indication
Formula / weight
C28H30N2O2 · 426.55 g/mol (avg)
First approval
Canada, 2016 · United States, 2004 · European Union, 2021
Code names
UK 88525 · UK 88525-04
Brand names
  • Emselex
  • Enablex

Resolves to

Compound
UNIIAPG9819VLMCAS133099-04-4ChEMBLCHEMBL1346ChEBI391960PubChem444031KEGGD01699
Clinical / RWD
RxNorm136198ATCG04BD10PharmGKBPA164774901
Structure
InChIKeyHXGBXQDTNZMWGS-RUZDIDTESA-NSMILESNC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
Targets
P20309CHRM3P08172CHRM2P11229CHRM1P08173CHRM4P08912CHRM5

What you can answer from here — as of September 23, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
862Drug interactionsStructured to mechanism, not free text
Sign in
19Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
144Marketed productsAcross 10 countries and 31 labellers
Sign in
1ATC codeIncluding every combination product, plus 18 drug categories
Sign in
31+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Darifenacin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In